#1 Clinical Trials Search in Europe

Tumour Detection

This article explores the use of Tumour Detection in clinical trials for advanced prostate cancer. These trials aim to evaluate the effectiveness of various treatments, including apalutamide and androgen deprivation therapy (ADT), in combination with Tumour Detection techniques. The studies focus on patients with high-risk, localized, or metastatic prostate cancer, assessing outcomes such as metastasis-free survival and pathological complete response rates.

Table of Contents

What is TUMOUR DETECTION?

TUMOUR DETECTION is a medical imaging agent used to identify and locate tumors in the body[1]. It belongs to a class of substances known as radiopharmaceuticals, which are drugs containing radioactive materials used for diagnostic or therapeutic purposes. In the case of TUMOUR DETECTION, its primary use is for diagnostic imaging, particularly in the field of oncology (cancer medicine).

How Does TUMOUR DETECTION Work?

TUMOUR DETECTION works by targeting specific molecules or processes associated with cancer cells. When injected into the body, it accumulates in areas where these cancer-related targets are present. The radioactive component of TUMOUR DETECTION then emits signals that can be detected by special cameras, creating detailed images of where the substance has concentrated. This allows doctors to visualize the location and extent of tumors with high precision[2].

Uses of TUMOUR DETECTION

TUMOUR DETECTION is primarily used in the diagnosis and management of prostate cancer, particularly in cases where the cancer is considered high-risk or has potentially spread beyond the prostate. Its main applications include:

  • Detecting the presence and location of prostate cancer
  • Determining if prostate cancer has spread to other parts of the body (metastasis)
  • Monitoring the response to treatment
  • Guiding treatment decisions

In clinical trials, TUMOUR DETECTION is being used in combination with other imaging techniques such as CT (Computed Tomography), MRI (Magnetic Resonance Imaging), and bone scans to provide a more comprehensive assessment of cancer spread[3].

How is TUMOUR DETECTION Administered?

TUMOUR DETECTION is typically administered through intravenous use, which means it is injected directly into a vein[1]. The exact dose can vary depending on the specific imaging procedure and the patient’s individual characteristics. In clinical trials, the dosage is carefully controlled and monitored to ensure patient safety while obtaining high-quality images.

Current Clinical Trials

TUMOUR DETECTION is currently being studied in several clinical trials for prostate cancer. These trials are investigating its use in different stages of the disease and in combination with various treatments. Some key studies include:

  1. A study evaluating TUMOUR DETECTION in patients with metastatic castration-sensitive prostate cancer (mCSPC) who are receiving treatment with apalutamide and androgen deprivation therapy (ADT)[1].
  2. A trial assessing TUMOUR DETECTION in patients with high-risk localized or locally advanced prostate cancer who are candidates for radiation therapy[2].
  3. A study using TUMOUR DETECTION to evaluate patients with high-risk prostate cancer before and after radical prostatectomy (surgical removal of the prostate)[3].

These trials aim to determine if TUMOUR DETECTION can improve the accuracy of cancer staging, help guide treatment decisions, and assess treatment effectiveness more precisely.

Safety and Side Effects

As with any medical procedure involving radiation, there are potential risks associated with TUMOUR DETECTION. However, these risks are generally considered low when the agent is used as directed by healthcare professionals. The radiation exposure from diagnostic procedures using TUMOUR DETECTION is carefully controlled to minimize risk while still providing valuable diagnostic information.

Patients should inform their healthcare providers of any allergies or previous reactions to medical contrast agents or radiopharmaceuticals before undergoing a procedure with TUMOUR DETECTION[2].

Conclusion

TUMOUR DETECTION represents an important advancement in cancer imaging, particularly for prostate cancer. By providing detailed information about the presence and spread of cancer, it can help doctors make more informed decisions about treatment strategies. As research continues, TUMOUR DETECTION may play an increasingly important role in personalizing cancer care and improving outcomes for patients with prostate cancer.

Aspect Details
Study Types Phase 3, randomized, double-blind, placebo-controlled trials
Primary Objectives Evaluate metastasis-free survival (MFS), pathological complete response (pCR) rates
Key Treatments Apalutamide, Androgen Deprivation Therapy (ADT), Radiation Therapy
Patient Population Adults with high-risk, localized, or metastatic prostate cancer
Imaging Techniques Conventional imaging (CT, MRI, bone scans), PSMA-PET imaging
Key Eligibility Criteria Specific Gleason scores, PSA levels, adequate organ function
Study Duration Varies, ranging from several months to years
Primary Endpoints MFS, pCR rate, radiographic progression-free survival

FAQ

  • What is Tumour Detection and how is it used in these clinical trials? Tumour Detection refers to imaging techniques used to identify and locate cancer cells in the body. In these trials, it's used to assess the presence of metastases and monitor treatment effectiveness. Techniques may include conventional imaging (CT, MRI, bone scans) and more advanced methods like PSMA-PET imaging.
  • Who is eligible to participate in these clinical trials? Eligibility varies by trial but generally includes adult men with high-risk, localized, or metastatic prostate cancer. Specific criteria may include factors like Gleason score, PSA levels, and absence of certain medical conditions. Patients must also be able to undergo the proposed treatments and follow study protocols.
  • What are the main objectives of these clinical trials? The main objectives include evaluating the effectiveness of treatments like apalutamide and ADT in improving outcomes such as metastasis-free survival, pathological complete response rates, and overall survival in patients with advanced prostate cancer. The trials also assess the safety and tolerability of these treatments.
  • How long do these clinical trials typically last? The duration varies by trial, but they can last from several months to several years. For example, one trial mentions a maximum treatment period of 900 days (about 2.5 years), while another indicates follow-up for up to 12 months after treatment.
  • What are some potential risks or side effects associated with participating in these trials? Potential risks may include side effects from the study drugs (like apalutamide) or procedures (like radiation therapy). Common side effects might include fatigue, hot flashes, and changes in liver function. There may also be risks associated with imaging procedures. However, participants are closely monitored throughout the trial for any adverse effects.

Ongoing Clinical Trials on Tumour Detection

  • Study on Apalutamide and Drug Combination for Patients with Metastatic Castration-Sensitive Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Poland

  • Study of Apalutamide and Androgen Deprivation Therapy for Patients with High-Risk Prostate Cancer

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Italy The Netherlands Poland +1

  • Study on the Effectiveness and Safety of Apalutamide and GnRH Agonist in Patients with High-Risk Prostate Cancer Undergoing Radiation Therapy

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Italy Poland +3

Glossary

  • Apalutamide: A type of drug known as an androgen receptor inhibitor, used to treat prostate cancer by blocking the effects of male hormones.
  • Androgen Deprivation Therapy (ADT): A treatment that reduces levels of male hormones in the body, which can slow the growth of prostate cancer.
  • Metastasis-Free Survival (MFS): The length of time during and after treatment that a patient lives without cancer spreading to other parts of the body.
  • PSMA-PET Imaging: A type of imaging that uses a radioactive tracer to detect prostate cancer cells throughout the body.
  • Gleason Score: A grading system used to determine the aggressiveness of prostate cancer based on how the cancer cells look under a microscope.
  • PSA (Prostate-Specific Antigen): A protein produced by the prostate gland. Elevated levels in the blood can indicate prostate cancer.
  • Radical Prostatectomy (RP): A surgical procedure to remove the entire prostate gland and surrounding tissues.
  • pLND (Pelvic Lymph Node Dissection): A surgical procedure to remove lymph nodes in the pelvic area, often performed during prostate cancer surgery.
  • Pathological Complete Response (pCR): The absence of all detectable cancer in tissue samples after treatment.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.

References

  1. http://clinicaltrials.eu/trial/study-on-apalutamide-and-drug-combination-for-patients-with-metastatic-castration-sensitive-prostate-cancer/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-apalutamide-and-gnrh-agonist-in-patients-with-high-risk-prostate-cancer-undergoing-radiation-therapy/
  3. http://clinicaltrials.eu/trial/study-of-apalutamide-and-androgen-deprivation-therapy-for-patients-with-high-risk-prostate-cancer/